AstraZeneca to acquire Icosavax in $1.1bn deal to boost vaccine development

AstraZeneca to acquire Icosavax in $1.1bn deal to boost vaccine development

In a definitive move, AstraZeneca has entered into an agreement to acquire Icosavax, Inc., a U.S.-based biopharmaceutical company specializing in innovative vaccines. This acquisition, valued at approximately $1.1 billion, signifies a major advancement in respiratory vaccine research, focusing on a novel protein virus-like particle (VLP) platform. The acquisition will significantly enhance AstraZeneca’s expertise in respiratory […]

Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics

Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics

Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth up to $330 million. The Japanese pharma major exercised its option to acquire the US pharma company following the completion of a phase 1 proof-of-mechanism study of the latter’s investigational […]